StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report released on Monday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of Brooklyn ImmunoTherapeutics stock opened at $2.16 on Monday. The stock has a market cap of $127.06 million, a price-to-earnings ratio of -0.98 and a beta of 4.61. The firm’s 50-day moving average is $2.19 and its two-hundred day moving average is $1.80. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.